Syndrome Clinical Trials in Houston, Texas
151 recruitingHouston, Texas
Showing 1–20 of 151 trials
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndromes+1 more
Orca Biosystems, Inc.300 enrolled11 locationsNCT03802695
Recruiting
Phase 2
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
Colorectal, CancerLynch SyndromeT Cells
M.D. Anderson Cancer Center40 enrolled1 locationNCT05411718
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 2
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729
Recruiting
Phase 2
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center76 enrolled1 locationNCT04239157
Recruiting
Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
A Registry for People With T-cell Lymphoma
T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Hematopoietic and Lymphoid Cell NeoplasmBronchiolitis Obliterans Syndrome
Fred Hutchinson Cancer Center250 enrolled4 locationsNCT05250037
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes
Hereditary Colorectal Cancer Syndrome
M.D. Anderson Cancer Center2,000 enrolled1 locationNCT02863172
Recruiting
Phase 1Phase 2
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmCOVID-19 Infection+2 more
M.D. Anderson Cancer Center70 enrolled1 locationNCT04565665
Recruiting
Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Seagen, a wholly owned subsidiary of Pfizer178 enrolled54 locationsNCT04227847
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 1Phase 2
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT04734990
Recruiting
Phase 1Phase 2
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+2 more
M.D. Anderson Cancer Center73 enrolled1 locationNCT03661307
Recruiting
Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acute Coronary Syndrome
DalCor Pharmaceuticals2,000 enrolled223 locationsNCT05918861
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 1
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+3 more
BlossomHill Therapeutics170 enrolled13 locationsNCT06501196